Inventor

HOVEYDA HAMID R

BE30 patents

⚠️ This page may combine multiple inventors who share the name “HOVEYDA HAMID R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

HOVEYDA HAMID R

OGEDA SA

Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof

N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof

NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders

NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders

Substituted pyrrolidines as G-protein coupled receptor 43 agonists

Substituted pyrrolidines as G-protein coupled receptor 43 agonists

NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders

TRANZYME PHARMA INC

Methods of using macrocyclic modulators of the ghrelin receptor

Macrocyclic modulators of the ghrelin receptor

Methods of treating cachexia with macrocyclic modulators of the ghrelin receptor

Methods of using macrocyclic modulators of the ghrelin receptor

Macrocyclic modulators of the ghrelin receptor

Spatially-defined macrocycles incorporating peptide bond surrogates

Spatially-defined macrocyclic compounds useful for drug discovery

MARSAULT ERIC

Processes for intermediates for macrocyclic compounds

Spatially-defined macrocyclic compounds useful for drug discovery

Processes for intermediates for macrocyclic compounds

EUROSCREEN SA

NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders

Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof

Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof

EPICS THERAPEUTICS

Substituted pyrrolidines as G-protein coupled receptor 43 agonists

Substituted pyrrolidines as G-protein coupled receptor 43 agonists

Substituted pyrrolidines as G-protein coupled receptor 43 agonists

UNIV BRITISH COLUMBIA

Methods of treating hypertension with vanadium compositions

Complexed vanadium for the treatment of diabetes mellitus

FRASER GRAEME L

Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders

Methods of using macrocyclic modulators of the ghrelin receptor

HOVEYDA HAMID R

Substituted pyrrolidines as G-protein coupled receptor 43 agonists

DESLONGCHAMPS PIERRE

Spatially-defined macrocycles incorporating peptide bond surrogates